- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04684732
Relationship Between Renal Function and Pharmacokinetics of Apixaban and Clinical Outcome of Apixaban in Thai Non-valvular Atrial Fibrillation Patients
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This study is divided into two parts.
The first part is a multiple dose pharmacokinetic and pharmacodynamics study of Apixaban in patient with stable renal function. The primary purpose of this study is to provide a clear understanding of the effect of creatinine clearance on pharmacokinetics and pharmacodynamics of Apixaban among Thai patients with nonvalvular atrial fibrillation. To assess the pharmacokinetics and pharmacodynamics of Apixaban, This study will enroll 30 subjects who meet the inclusion criteria.
The second part of this study will retrospectively determine the occurrent of clinical outcome between patients who were prescribed apixaban dose concordant and discordant to the drug leaflet. A total of 241 subjects will be recruited. The follow up period will begin from the time of initiation of apixaban until occurrent of stoke, transient ischemic attack, systemic embolism, bleeding, or death.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
Bangkok
-
Pathum Wan, Bangkok, Tailandia, 10330
- King Chulalongkorn Memorial Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Part I
Inclusion Criteria:
- Patients with nonvalvular atrial fibrillation
- Patients who is receiving a stable dose of apixaban for primary or secondary prevention of stroke, transient ischemic attack, and systemic embolism.
Exclusion Criteria:
- Pregnant or lactating
- End stage renal disease patients who required chronic renal replacement therapy to sustained life
- History of acute kidney injury within the previous 3 months
- Severe hepatic impairment (Child-Pugh class C)
- Any gastrointestinal disorder that could impact the absorption of study drug
- CYP3A4 Moderate/Strong Inhibitors: ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, naproxen, clarithromycin, rifampicin, phenytoin, carbamazepine, phenobarbital, diltiazem, and St.John's Wort
Part II
Inclusion Criteria:
- Patients with nonvalvular atrial fibrillation
- Patients who was prescribed apixaban for primary or secondary prevention of stroke, transient ischemic attack, and systemic embolism.
Exclusion Criteria:
- Pregnant or lactating
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
---|
Apixaban dose concordant to leaflet
Patients who were prescribed apixaban dose concordant to apixaban leaflet approved by Thai FDA
|
Apixaban dose discordant to leaflet
Patients who were prescribed apixaban dose discordant to apixaban leaflet approved by Thai FDA
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Steady state area under the concentration-time curve from pre-dose to 12 hours post-dose (AUC(0-12)) of Apixaban
Lasso di tempo: pre-dose to 12 hours post-dose
|
AUC(0-12) is measured by plasma concentration of apixaban over time.
The mean are reported in nanogram hours per milliliter (ng*h/mL).
|
pre-dose to 12 hours post-dose
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of participants with first event of stroke, transient ischemic attack, systemic embolism (SE), or all-cause death during the follow up period
Lasso di tempo: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed until July 31, 2020
|
Diagnosis of stroke is defined as the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction).
Diagnosis of SE is defined as a clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed until July 31, 2020
|
Number of patients with event of major or nonmajor (International Society on Thrombosis and Hemostasis [ISTH]) bleeding during the follow up period
Lasso di tempo: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed until July 31, 2020
|
ISTH major bleeding criteria is defined as a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal. ISTH nonmajor bleeding is defined as clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy. |
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed until July 31, 2020
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Steady-state maximum observed plasma concentration of Apixaban
Lasso di tempo: pre-dose to 12 hours post-dose
|
Maximum observed drug concentration in plasma after administration (Cmax) of apixaban at steady-state
|
pre-dose to 12 hours post-dose
|
Steady-state minimum observed plasma concentration of Apixaban
Lasso di tempo: pre-dose to 12 hours post-dose
|
Minimum observed drug concentration in plasma after administration (Cmin) of apixaban at steady-state
|
pre-dose to 12 hours post-dose
|
Steady state elimination of half-life of Apixaban
Lasso di tempo: pre-dose to 12 hours post-dose
|
Mean terminal phase plasma t½ of apixaban at steady-state
|
pre-dose to 12 hours post-dose
|
Steady state Anti-Xa activity
Lasso di tempo: pre-dose to 12 hours post-dose
|
Anti-Xa activity will be measured by chromogenic anti-Xa activity assay
|
pre-dose to 12 hours post-dose
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 632/63
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .